The group’s principle activities include developing and commercializing neuroprotective medicines for the treatment of central nervous system disorders. The group also has preclinical programs underway in depression, pain, Alzheimer’s disease, Parkinson's disease, multiple sclerosis and epilepsy. The group operates from United States.
